AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies

Bibliography

• Gruber HE, Hoffer ME, McAllister DR, Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury. Circulation 1989;80:1400-11
   PubMed Web of Science ®Google Scholar
• Vincent MF, Marangos PJ, Gruber HE, Van den Berghe G. Inhibition by AICA riboside of gluconeogenesis in isolated rat hepatocytes. Diabetes 1991;40:1259-66
   PubMed Web of Science ®Google Scholar
• Van den Berghe G, Gruber H. Method for lowering blood lipid levels. WO9303734; 1993
   Google Scholar
• Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase – development of the energy sensor concept. J Physiol 2006;574:7-15
   PubMed Web of Science ®Google Scholar
• Sullivan JE, Brocklehurst KJ, Marley AE, Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett 1994;353:33-6
   PubMed Web of Science ®Google Scholar
• Bochner BR, Ames BN. ZTP (5-amino 4-imidazole carboxamide riboside 5′-triphosphate): a proposed alarmone for 10-formyl-tetrahydrofolate deficiency. Cell 1982;29:929-37
   PubMed Web of Science ®Google Scholar
• Carling D, Clarke PR, Zammit VA, Hardie DG. Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities. Eur J Biochem 1989;186:129-36
   PubMedGoogle Scholar
• Henin N, Vincent MF, Gruber HE, Van den Berghe G. Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase. FASEB J 1995;9:541-6
   PubMed Web of Science ®Google Scholar
• Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 1995;229:558-65
   PubMedGoogle Scholar
• Hardie DG. AMP-activated protein kinase: the guardian of cardiac energy status. J Clin Invent 2004;117:465-8
   Google Scholar
• Dixon R, Gourzis J, McDermott D, AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. J Clin Pharmacol 1991;31:342-7
   PubMed Web of Science ®Google Scholar
• Drew BG, Kingwell BA. Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin Pharmacother 2008;9:2137-44
   PubMed Web of Science ®Google Scholar
• Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999;277:E1-10
   PubMed Web of Science ®Google Scholar
• Vincent MF, Erion MD, Gruber HE, Van den Berghe G. Hypoglycaemic effect of AICAriboside in mice. Diabetologia 1996;39:1148-55
   PubMed Web of Science ®Google Scholar
• Bergeron R, Previs SF, Cline GW, Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 2001;50:1076-82
   PubMed Web of Science ®Google Scholar
• Schimmack G, Defronzo RA, Musi N. AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes Metab 2006;8:591-602
   PubMed Web of Science ®Google Scholar
• Consoli A, Nurjhan N, Capani F, Gerich J. Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 1989;38:550-7
   PubMed Web of Science ®Google Scholar
• Erion MD, van Poelje PD, Dang Q, MB06322 (CS-917): a potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc Natl Acad Sci USA 2005;102:7970-5
   PubMed Web of Science ®Google Scholar
• van Poelje PD, Potter SC, Chandramouli VC, Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats. Diabetes 2006;55:1747-54
   PubMed Web of Science ®Google Scholar
• Gumbiner B, Bullough D, Watling S, Pronounced glucose (G) reduction in poorly controlled T2DM with MB07803, a novel fructose-1,6-bisphosphatase inhibitor (FBPaseI) with reduced potential for acid-base disturbance vs the 1st generation FBPaseI CS-917. Late breaking abstract nr 11-LB, presented at the 69th Meeting of the American Diabetes Association; 5 – 9 June 2009; New Orleans, LA
   Google Scholar
• Merrill GF, Kurth EJ, Hardie DG, Winder WW. AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol 1997;273:E1107-12
   PubMed Web of Science ®Google Scholar
• Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, Winder WW. 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 1999;48:1667-71
   PubMed Web of Science ®Google Scholar
• Narkar VA, Downes M, Yu RT, AMPK and PPARdelta agonists are exercise mimetics. Cell 2008;134:405-15
   PubMed Web of Science ®Google Scholar
• Goransson O, McBride A, Hawley SA, Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem 2007;282:32549-60
   PubMed Web of Science ®Google Scholar
• Richter EA, Kiens B, Wojtaszewski JF. Can exercise mimetics substitute for exercise? Cell Metab 2008;8:96-8
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20
   PubMed Web of Science ®Google Scholar
• Weinberg F, Chandel NS. Mitochondrial metabolism and cancer. Ann NY Acad Sci 2009;1177:66-73
   PubMed Web of Science ®Google Scholar
• Xiang X, Saha AK, Wen R, AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 2004;321:161-7
   PubMed Web of Science ®Google Scholar
• Swinnen JV, Beckers A, Brusselmans K, Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res 2005;65:2441-8
   PubMed Web of Science ®Google Scholar
• Rattan R, Giri S, Singh AK, Singh I. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 2005;280:39582-93
   PubMed Web of Science ®Google Scholar
• Baumann P, Mandl-Weber S, Emmerich B, Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells. Exp Cell Res 2007;313:3592-603
   PubMed Web of Science ®Google Scholar
• Beckers A, Organe S, Timmermans L, Methotrexate enhances the antianabolic and antiproliferative effects of 5-aminoimidazole-4-carboxamide riboside. Mol Cancer Ther 2006;5:2211-17
   PubMed Web of Science ®Google Scholar
• Garcia-Gil M, Pesi R, Perna S, 5′-aminoimidazole-4-carboxamide riboside induces apoptosis in human neuroblastoma cells. Neuroscience 2003;117:811-20
   PubMedGoogle Scholar
• Pesi R, Micheli V, Jacomelli G, Cytosolic 5′-nucleotidase hyperactivity in erythrocytes of Lesch-Nyhan syndrome patients. Neuroreport 2000;11:1827-31
   PubMed Web of Science ®Google Scholar
• Kefas BA, Heimberg H, Vaulont S, AICA-riboside induces apoptosis of pancreatic beta cells through stimulation of AMP-activated protein kinase. Diabetologia 2003;46:250-4
   PubMed Web of Science ®Google Scholar
• Meisse D, Van de Casteele M, Beauloye C, Sustained activation of AMP-activated protein kinase induces c-Jun N-terminal kinase activation and apoptosis in liver cells. FEBS Lett 2002;526:38-42
   PubMed Web of Science ®Google Scholar
• Campas C, Lopez JM, Santidrian AF, Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood 2003;101:3674-80
   PubMed Web of Science ®Google Scholar
• Campas C, Santidrian AF, Domingo A, Gil J. Acadesine induces apoptosis in B cells from mantle cell lymphoma and splenic marginal zone lymphoma. Leukemia 2005;19:292-4
   PubMed Web of Science ®Google Scholar
• Lopez JM, Santidrian AF, Campas C, Gil J. 5-Aminoimidazole-4-carboxamide riboside induces apoptosis in Jurkat cells, but the AMP-activated protein kinase is not involved. Biochem J 2003;370:1027-32
   PubMed Web of Science ®Google Scholar
• Stefanelli C, Stanic I, Bonavita F, Inhibition of glucocorticoid-induced apoptosis with 5-aminoimidazole-4-carboxamide ribonucleoside, a cell-permeable activator of AMP-activated protein kinase. Biochem Biophys Res Commun 1998;243:821-6
   PubMed Web of Science ®Google Scholar
• Culmsee C, Monnig J, Kemp BE, Mattson MP. AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J Mol Neurosci 2001;17:45-58
   PubMed Web of Science ®Google Scholar
• Ido Y, Carling D, Ruderman N. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 2002;51:159-67
   PubMed Web of Science ®Google Scholar
• Blazquez C, Geelen MJ, Velasco G, Guzman M. The AMP-activated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes. FEBS Lett 2001;489:149-53
   PubMed Web of Science ®Google Scholar
• Nishino Y, Miura T, Miki T, Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 up-regulation in the late phase of cardioprotection. Cardiovasc Res 2004;61:610-19
   PubMed Web of Science ®Google Scholar
• Russell RR III, Li J, Coven DL, AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 2004;114:495-503
   PubMed Web of Science ®Google Scholar
• Jacobs RL, Lingrell S, Dyck JR, Vance DE. Inhibition of hepatic phosphatidylcholine synthesis by 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside is independent of AMP-activated protein kinase activation. J Biol Chem 2007;282:4516-23
   PubMed Web of Science ®Google Scholar
• Meley D, Bauvy C, Houben-Weerts JH, AMP-activated protein kinase and the regulation of autophagic proteolysis. J Biol Chem 2006;281:34870-9
   PubMed Web of Science ®Google Scholar
• Guigas B, Taleux N, Foretz M, AMP-activated protein kinase-independent inhibition of hepatic mitochondrial oxidative phosphorylation by AICA riboside. Biochem J 2007;404:499-507
   PubMed Web of Science ®Google Scholar
• Imamura K, Ogura T, Kishimoto A, Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 2001;287:562-7
   PubMedGoogle Scholar
• Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer 2007;6:46
   PubMed Web of Science ®Google Scholar
• Coll-Mulet L, Iglesias-Serret D, Santidrian AF, MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006;107:4109-14
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M, Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-88
   PubMed Web of Science ®Google Scholar
• Wierda W, O'Brien S, Wen S, Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070-8
   PubMed Web of Science ®Google Scholar
• Hallek M, Fingerle-Rowson G, Fink A-M, Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts. Blood 2008;112:325
   Google Scholar
• Bosch F, Abrisqueta P, Villamor N, Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009;27:4578-84
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Kay NE. Comprehensive management of the CLL patient: a holistic approach. Hematology Am Soc Hematol Educ Program 2007;2007:324-31
   Google Scholar
• Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007;25:1824-31
   PubMed Web of Science ®Google Scholar
• Morrison VA. Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2007;2007:332-8
   Google Scholar
• Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009;115:2824-36
   PubMed Web of Science ®Google Scholar
• O'Brien S. New agents in the treatment of CLL. Hematology Am Soc Hematol Educ Program 2008;2008:457-64
   Google Scholar
• Zenz T, Benner A, Dohner H, Stilgenbauer S. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle 2008;7:3810-14
   PubMed Web of Science ®Google Scholar
• Calissano C, Damle RN, Hayes G, In vivo intra- and inter-clonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood 2009;114:4832-42
   Google Scholar
• Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008;2008:450-6
   Google Scholar
• Maddocks KJ, Lin TS. Update in the management of chronic lymphocytic leukemia. J Hematol Oncol 2009;2:29
   PubMedGoogle Scholar
• Zenz T, Habe S, Denzel T, Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009;114:2589-97
   PubMed Web of Science ®Google Scholar
• Andersen NS, Pedersen LB, Laurell A, Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009;27:4365-70
   PubMed Web of Science ®Google Scholar